Patents by Inventor Tatsuki Koike

Tatsuki Koike has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12091410
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: September 17, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Yasutaka Hoashi, Yasushi Hattori, Norihito Tokunaga, Tsuneo Oda, Tohru Miyazaki, Dilhumar Uyghur, Yoshiteru Ito, Kohei Takeuchi, Keisuke Imamura, Takahiro Sugimoto, Koichiro Fukuda, Yasuhisa Kohara, Rei Okamoto, Taiichi Ohra, Naoki Miyamoto, Yoshito Terao, Masanori Kawasaki
  • Patent number: 12077522
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: September 3, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Koichiro Fukuda, Hiromichi Sugimoto, Kentaro Rikimaru, Yoshihiro Banno, Takahiro Matsumoto, Norihito Tokunaga, Yoshihide Tomata, Yuji Ishichi, Shogo Marui, Tsuneo Oda, Tohru Miyazaki, Yasutaka Hoashi, Yasushi Hattori, Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike
  • Patent number: 12071434
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: August 27, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuhei Miyanohana, Yuichi Kajita, Tatsuki Koike, Yasutaka Hoashi, Yasushi Hattori, Norihito Tokunaga, Tsuneo Oda, Tohru Miyazaki, Dilhumar Uyghur, Yoshiteru Ito, Kohei Takeuchi, Keisuke Imamura, Takahiro Sugimoto, Koichiro Fukuda, Yasuhisa Kohara, Rei Okamoto, Taiichi Ohra, Naoki Miyamoto, Jun Chiba, Yoshito Terao, Masanori Kawasaki
  • Patent number: 11987586
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: October 30, 2023
    Date of Patent: May 21, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yasushi Hattori, Marilena Pira, Yoshiteru Ito, Kohei Takeuchi, Eiji Kimura, Norihito Tokunaga, Shuhei Ikeda, Martin Alexander Pawliczek, Noriyuki Tezuka, Yasutaka Hoashi, Yuhei Miyanohana, Yuichi Kajita, Tatsuki Koike
  • Patent number: 11655241
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: May 23, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo Oda, Yoshiteru Ito, Tohru Miyazaki, Kohei Takeuchi, Norihito Tokunaga, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura, Yuichi Kajita, Yuhei Miyanohana, Takahiro Sugimoto, Tatsuki Koike, Dilhumar Uyghur
  • Patent number: 11495331
    Abstract: An objective of the present invention is to provide a document creation assistance server and document creation assistance method which are capable of efficiently acquiring information necessary to write a specification or other such documents, and of generating a document from the acquired information.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: November 8, 2022
    Assignees: TAKEDA PHARMACEUTICAL COMPANY LIMITED, PATCORE, INC.
    Inventors: Hiroshi Nara, Junya Shirai, Tatsuki Koike, Kenjiro Sato, Takaharu Hirayama, Hiromi Fukuda, Tsutomu Morita, Hiromasa Ishihara, Kazue Suzuki, Hiroki Sakamoto, Fumiaki Kikuchi, Kenta Tamaki, Toru Tanoue, Yuichi Horita, Takeshi Ueda
  • Patent number: 11440883
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: September 13, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Kohei Takeuchi, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tohru Miyazaki, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • Patent number: 11319286
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: May 3, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto, Yuichi Kajita, Satoshi Mikami, Yuhei Miyanohana, Tatsuki Koike, Masaki Daini, Masaki Ogino, Kohei Takeuchi, Tohru Miyazaki, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • Patent number: 11174272
    Abstract: The present invention provides a compound useful as an agent for the prophylaxis or treatment of neurodegenerative disease and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: November 16, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tatsuki Koike, Masato Yoshikawa, Haruhi Ando, William John Farnaby
  • Patent number: 11059780
    Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: July 13, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masaki Daini, Yuhei Miyanohana, Satoshi Mikami, Yuichi Kajita, Masaki Ogino, Tatsuki Koike, Kohei Takeuchi
  • Patent number: 11034700
    Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: June 15, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Satoshi Mikami, Masaki Daini, Yuhei Miyanohana, Hideo Suzuki, Kenichiro Shimokawa, Yuichi Kajita, Masaki Ogino, Tatsuki Koike, Kohei Takeuchi
  • Patent number: 11028048
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: June 8, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yasushi Hattori, Yuhei Miyanohana, Yuichi Kajita, Tatsuki Koike, Yasutaka Hoashi, Norihito Tokunaga, Alexander Martin Pawliczek, Tsuneo Oda, Tohru Miyazaki, Marilena Pira, Javier Miguelez-Ramos
  • Publication number: 20200247747
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: January 30, 2020
    Publication date: August 6, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yasushi Hattori, Yuhei Miyanohana, Yuichi Kajita, Tatsuki Koike, Yasutaka Hoashi, Norihito Tokunaga, Alexander Martin Pawliczek, Tsuneo Oda, Tohru Miyazaki, Yoshiteru Ito, Kohei Takeuchi, Keisuke Imamura, Takahiro Sugimoto
  • Patent number: 10717748
    Abstract: The present invention provides a compound useful as an agent for the prophylaxis or treatment of neurodegenerative disease and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: July 21, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tatsuki Koike, Masato Yoshikawa, Haruhi Ando, William John Farnaby
  • Patent number: 10584097
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: March 10, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Kohei Takeuchi, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tohru Miyazaki, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • Patent number: 10550129
    Abstract: The present invention provides a compound useful as an agent for the prophylaxis or treatment of neurodegenerative disease and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: February 4, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tatsuki Koike, Masato Yoshikawa, Haruhi Ando, William John Farnaby
  • Patent number: 10548877
    Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: February 4, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masaki Ogino, Eiji Kimura, Shinkichi Suzuki, Kouji Fuji, Tomohiro Ohashi, Makoto Fushimi, Kei Masuda, Tatsuki Koike, Takeshi Wakabayashi, Jinichi Yonemori, Masami Yamada
  • Patent number: 10428023
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: October 1, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Kohei Takeuchi, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tohru Miyazaki, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • Patent number: 10273245
    Abstract: The present invention provides a compound useful as an agent for the prophylaxis or treatment of neurodegenerative disease and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: April 30, 2019
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tatsuki Koike, Masato Yoshikawa, Haruhi Ando, William John Farnaby
  • Patent number: 10202376
    Abstract: Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: February 12, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Eiji Kimura, Yuhei Miyanohana, Masaki Ogino, Yuta Tanaka, Makoto Fushimi, Tomohiro Okawa, Yuki Hanya, Tatsuki Koike